Clovis Oncology Completes US, EU Regulatory Submissions for Rociletinib for Treatment of Advanced EGFR-Mutant T790M+ NSCLC
August 03, 2015 at 06:03 AM EDT
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that it has submitted its New Drug Application (NDA) regulatory ...